Estrogen receptor activation - Good, aldosterone receptor blockade - Beneficial, communication between receptors...priceless

Hypertension

Volumn 50, Issue 2, 2007, Pages 297-298

  Barbato, John C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; SPIRONOLACTONE;

CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; ESTROGEN THERAPY; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS; VASCULAR FIBROSIS;

ALDOSTERONE ANTAGONISTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ALDOSTERONE; RECEPTORS, ESTROGEN; RECEPTORS, MINERALOCORTICOID; RISK FACTORS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 34547645391     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.092437     Document Type: Editorial

References (10)

1. Mueck AO, Seeger H. Estrogens acting as cardiovascular agents: direct vascular actions. Curr Med Chem Cardiovascular Agents. 2004;2:35-42.
2. Pitt B. The role of aldosterone blockade in patients with heart failure. Heart Fail Rev. 2005;10:79-83.
3. Xin H-B, Senbonmatsu T, Cheng D-S, Wang Y-X, Copello JA, Ji G-J, Collier ML, Geng K-Y, Jeyakumar LH, Magnuson MA, Inagami T, Kotlikoff MI, Fleischer S. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature. 2002;416:334-337.
4. Babiker FA, DeWindt LJ, van Eickels M, Thijssen V, Bronsaer RJP, Grohe C, van Bilsen M, Doevendans PA. 17β-Estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation. 2004;109:269-276.
5. Delcayre C, Silvestre JS. Aldosterone and the heart: towards a physiological function? Cardiovasc Res. 1999;43:7-12.
6. Arias-Loza P-A, Hu K, Dienesch C, Mehlich AM, König S, Jazbutyte V, Neyses L, Hegele-Hartung C, Fritzemeier KH, Pelzer T. Both estrogen receptor subtypes, α and β, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension. 2007;50:432-438.
7. Terry-Lorenzo RT, Elliot E, Weiser DC, Prickett TD, Brautigan DL, Shenolikar S. Neurabins recruit protein phosphatase-1 and inhibitor-2 to the cytoskeleton. J Biol Chem. 2002;277:46535-46543.
8. Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing S-L, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol. 2002;22:4124-4135.
9. Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol. 1998;32:1118-1125.
10. Palmer BM. Thick filament proteins and performance in human heart failure. Heart Fail Rev. 2005;10:187-197.